{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:09:50Z","timestamp":1778126990964,"version":"3.51.4"},"reference-count":211,"publisher":"Bentham Science Publishers Ltd.","issue":"29","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,10,21]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The Endocannabinoid (eCB) system and its role in many physiological and pathological conditions is\nwell described and accepted, and includes cardiovascular disorders. However, the eCB system has been expanded\nto an \u201c-ome\u201d; the endocannabinoidome (eCBome) that includes endocannabinoid-related mediators, their protein\ntargets and metabolic enzymes, many of which significantly impact upon cardiometabolic health. These recent\ndiscoveries are here summarized with a special focus on their potential involvement in atherosclerosis. We described\nthe role of classical components of the eCB system (eCBs, CB1 and CB2 receptors) and eCB-related lipids,\ntheir regulatory enzymes and molecular targets in atherosclerosis. Furthermore, since increasing evidence\npoints to significant cross-talk between the eCBome and the gut microbiome and the gut microbiome and atherosclerosis,\nwe explore the possibility that a gut microbiome - eCBome axis has potential implications in atherosclerosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190826162735","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:08:13Z","timestamp":1566835693000},"page":"3147-3164","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of the Endocannabinoidome in Human and Mouse Atherosclerosis"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-4622","authenticated-orcid":true,"given":"Fabiana","family":"Piscitelli","sequence":"first","affiliation":[{"name":"Institute of Biomolecular Chemistry, National Council of Research, Pozzuoli (NA), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5635-1545","authenticated-orcid":true,"given":"Cristoforo","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Laval University, Quebec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"Devane W.A.","year":"1992","unstructured":"Devane W.A.; Hanus L.; Breuer A.; Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992,258(5090),1946-1949","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","volume":"50","author":"Mechoulam R.","year":"1995","unstructured":"Mechoulam R.; Ben-Shabat S.; Hanus L.; Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995,50(1),83-90","journal-title":"Biochem Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"Devane W.A.","year":"1992","unstructured":"Devane W.A.; Hanus L.; Breuer A.; Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992,258(5090),1946-1949","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"Matsuda L.A.","year":"1990","unstructured":"Matsuda L.A.; Lolait S.J.; Brownstein M.J.; Young A.C.; Bonner T.I.; Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990,346(6284),561-564","journal-title":"Nature"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"Munro S.","year":"1993","unstructured":"Munro S.; Thomas K.L.; Abu-Shaar M.; Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993,365(6441),61-65","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"Howlett A.C.","year":"2002","unstructured":"Howlett A.C.; Barth F.; Bonner T.I.; International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002,54(2),161-202","journal-title":"Pharmacol Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0376-8716(98)00075-1","volume":"51","author":"Childers S.R.","year":"1998","unstructured":"Childers S.R.; Breivogel C.S.; Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998,51(1-2),173-187","journal-title":"Drug Alcohol Depend"},{"key":"ref=8","first-page":"532","volume":"26","author":"Howlett A.C.","year":"1984","unstructured":"Howlett A.C.; Fleming R.M.; Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984,26(3),532-538","journal-title":"Mol Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1476-5381.1992.tb14321.x","volume":"106","author":"Caulfield M.P.","year":"1992","unstructured":"Caulfield M.P.; Brown D.A.; Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992,106(2),231-232","journal-title":"Br J Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1073\/pnas.89.9.3825","volume":"89","author":"Mackie K.","year":"1992","unstructured":"Mackie K.; Hille B.; Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992,89(9),3825-3829","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1523\/JNEUROSCI.15-10-06552.1995","volume":"15","author":"Mackie K.","year":"1995","unstructured":"Mackie K.; Lai Y.; Westenbroek R.; Mitchell R.; Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995,15(10),6552-6561","journal-title":"J Neurosci"},{"key":"ref=12","first-page":"734","volume":"273","author":"Deadwyler S.A.","year":"1995","unstructured":"Deadwyler S.A.; Hampson R.E.; Mu J.; Whyte A.; Childers S.; Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 1995,273(2),734-743","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1042\/bj3120637","volume":"312","author":"Bouaboula M.","year":"1995","unstructured":"Bouaboula M.; Poinot-Chazel C.; Bourri\u00e9 B.; Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995,312(Pt 2),637-641","journal-title":"Biochem J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","volume":"78","author":"Demuth D.G.","year":"2006","unstructured":"Demuth D.G.; Molleman A.; Cannabinoid signalling. Life Sci 2006,78(6),549-563","journal-title":"Life Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"Herkenham M.","year":"1990","unstructured":"Herkenham M.; Lynn A.B.; Little M.D.; Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990,87(5),1932-1936","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"Herkenham M.","year":"1991","unstructured":"Herkenham M.; Lynn A.B.; Johnson M.R.; Melvin L.S.; de Costa B.R.; Rice K.C.; Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991,11(2),563-583","journal-title":"J Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","volume":"83","author":"Tsou K.","year":"1998","unstructured":"Tsou K.; Brown S.; Sa\u00f1udo-Pe\u00f1a M.C.; Mackie K.; Walker J.M.; Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998,83(2),393-411","journal-title":"Neuroscience"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/14734220410019011","volume":"3","author":"Ashton J.C.","year":"2004","unstructured":"Ashton J.C.; Appleton I.; Darlington C.L.; Smith P.F.; Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum. Cerebellum 2004,3(4),222-226","journal-title":"Cerebellum"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00125-007-0890-y","volume":"51","author":"Berm\u00fadez-Silva F.J.","year":"2008","unstructured":"Berm\u00fadez-Silva F.J.; Su\u00e1rez J.; Baixeras E.; Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008,51(3),476-487","journal-title":"Diabetologia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1523\/JNEUROSCI.19-11-04544.1999","volume":"19","author":"Katona I.","year":"1999","unstructured":"Katona I.; Sperl\u00e1gh B.; S\u00edk A.; Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999,19(11),4544-4558","journal-title":"J Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1096-9861(20000626)422:2<159:AID-CNE1>3.0.CO;2-1","volume":"422","author":"Egertov\u00e1 M.","year":"2000","unstructured":"Egertov\u00e1 M.; Elphick M.R.; Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 2000,422(2),159-171","journal-title":"J Comp Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1523\/JNEUROSCI.0309-06.2006","volume":"26","author":"Katona I.","year":"2006","unstructured":"Katona I.; Urb\u00e1n G.M.; Wallace M.; Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 2006,26(21),5628-5637","journal-title":"J Neurosci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1523\/JNEUROSCI.4872-05.2006","volume":"26","author":"Kawamura Y.","year":"2006","unstructured":"Kawamura Y.; Fukaya M.; Maejima T.; The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 2006,26(11),2991-3001","journal-title":"J Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.neuroscience.2006.01.024","volume":"139","author":"Takahashi K.A.","year":"2006","unstructured":"Takahashi K.A.; Castillo P.E.; The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 2006,139(3),795-802","journal-title":"Neuroscience"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"Gali\u00e8gue S.","year":"1995","unstructured":"Gali\u00e8gue S.; Mary S.; Marchand J.; Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995,232(1),54-61","journal-title":"Eur J Biochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","volume":"74","author":"Pertwee R.G.","year":"1997","unstructured":"Pertwee R.G.; Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997,74(2),129-180","journal-title":"Pharmacol Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjp.0702337","volume":"126","author":"Niederhoffer N.","year":"1999","unstructured":"Niederhoffer N.; Szabo B.; Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 1999,126(2),457-466","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.HYP.28.4.682","volume":"28","author":"Varga K.","year":"1996","unstructured":"Varga K.; Lake K.D.; Huangfu D.; Guyenet P.G.; Kunos G.; Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 1996,28(4),682-686","journal-title":"Hypertension"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10286-017-0488-5","volume":"28","author":"Sierra S.","year":"2018","unstructured":"Sierra S.; Luquin N.; Navarro-Otano J.; The endocannabinoid system in cardiovascular function: novel insights and clinical implications. Clin Auton Res 2018,28(1),35-52","journal-title":"Clin Auton Res"},{"key":"ref=30","first-page":"58","volume":"29","author":"Mallat A.","year":"2006","unstructured":"Mallat A.; Lotersztajn S.; Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006,29(3)(Suppl.),58-65","journal-title":"J Endocrinol Invest"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/138161208783330790","volume":"14","author":"Starowicz K.","year":"2008","unstructured":"Starowicz K.; Cristino L.; Di Marzo V.; TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008,14(1),42-54","journal-title":"Curr Pharm Des"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2007.09.099","volume":"364","author":"Cavuoto P.","year":"2007","unstructured":"Cavuoto P.; McAinch A.J.; Hatzinikolas G.; Janovsk\u00e1 A.; Game P.; Wittert G.A.; The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007,364(1),105-110","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","volume":"310","author":"Van Sickle M.D.","year":"2005","unstructured":"Van Sickle M.D.; Duncan M.; Kingsley P.J.; Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005,310(5746),329-332","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1196\/annals.1432.037","volume":"1139","author":"Brusco A.","year":"2008","unstructured":"Brusco A.; Tagliaferro P.A.; Saez T.; Onaivi E.S.; Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci 2008,1139,450-457","journal-title":"Ann N Y Acad Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","volume":"1071","author":"Gong J-P.","year":"2006","unstructured":"Gong J-P.; Onaivi E.S.; Ishiguro H.; Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006,1071(1),10-23","journal-title":"Brain Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1196\/annals.1369.052","volume":"1074","author":"Onaivi E.S.","year":"2006","unstructured":"Onaivi E.S.; Ishiguro H.; Gong J-P.; Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006,1074,514-536","journal-title":"Ann N Y Acad Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1155\/2001\/326867","volume":"6","author":"Klein T.W.","year":"2001","unstructured":"Klein T.W.; Newton C.A.; Friedman H.; Cannabinoids and the immune system. Pain Res Manag 2001,6(2),95-101","journal-title":"Pain Res Manag"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.clim.2006.11.002","volume":"122","author":"Lombard C.","year":"2007","unstructured":"Lombard C.; Nagarkatti M.; Nagarkatti P.; CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 2007,122(3),259-270","journal-title":"Clin Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","volume":"23","author":"Benito C.","year":"2003","unstructured":"Benito C.; N\u00fa\u00f1ez E.; Tol\u00f3n R.M.; Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains. J Neurosci 2003,23(35),11136-11141","journal-title":"J Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","volume":"153","author":"Benito C.","year":"2008","unstructured":"Benito C.; Tol\u00f3n R.M.; Pazos M.R.; N\u00fa\u00f1ez E.; Castillo A.I.; Romero J.; Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 2008,153(2),277-285","journal-title":"Br J Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","volume":"95","author":"Maresz K.","year":"2005","unstructured":"Maresz K.; Carrier E.J.; Ponomarev E.D.; Hillard C.J.; Dittel B.N.; Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005,95(2),437-445","journal-title":"J Neurochem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1871529X18666180206161457","volume":"18","author":"Fulmer M.L.","year":"2018","unstructured":"Fulmer M.L.; Thewke D.P.; The endocannabinoid system and heart disease: the role of cannabinoid receptor type 2. Cardiovasc Hematol Disord Drug Targets 2018,18(1),34-51","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/35071088","volume":"410","author":"Di Marzo V.","year":"2001","unstructured":"Di Marzo V.; Goparaju S.K.; Wang L.; Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001,410(6830),822-825","journal-title":"Nature"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","volume":"36","author":"Maccarrone M.","year":"2015","unstructured":"Maccarrone M.; Bab I.; B\u00edr\u00f3 T.; Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 2015,36(5),277-296","journal-title":"Trends Pharmacol Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","volume":"17","author":"Silvestri C.","year":"2013","unstructured":"Silvestri C.; Di Marzo V.; The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013,17(4),475-490","journal-title":"Cell Metab"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"Iannotti F.A.","year":"2016","unstructured":"Iannotti F.A.; Di Marzo V.; Petrosino S.; Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res 2016,62,107-128","journal-title":"Prog Lipid Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1098\/rstb.2000.0787","volume":"356","author":"Elphick M.R.","year":"2001","unstructured":"Elphick M.R.; Egertov\u00e1 M.; The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001,356(1407),381-408","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=48","author":"Di Marzo V.","year":"2014","unstructured":"Di Marzo V.; Wang J.;  The endocannabinoidome: The world of endocannabinoids and related mediators 2014","journal-title":"The endocannabinoidome: The world of endocannabinoids and related mediators"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd.2018.115","volume":"17","author":"Di Marzo V.","year":"2018","unstructured":"Di Marzo V.; New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018,17(9),623-639","journal-title":"Nat Rev Drug Discov"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11745-008-3217-y","volume":"43","author":"Thabuis C.","year":"2008","unstructured":"Thabuis C.; Tissot-Favre D.; Bezelgues J-B.; Biological functions and metabolism of oleoylethanolamide. Lipids 2008,43(10),887-894","journal-title":"Lipids"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.pain.2008.06.003","volume":"139","author":"Costa B.","year":"2008","unstructured":"Costa B.; Comelli F.; Bettoni I.; Colleoni M.; Giagnoni G.; The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008,139(3),541-550","journal-title":"Pain"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.lfs.2005.05.012","volume":"77","author":"LoVerme J.","year":"2005","unstructured":"LoVerme J.; La Rana G.; Russo R.; Calignano A.; Piomelli D.; The search for the palmitoylethanolamide receptor. Life Sci 2005,77(14),1685-1698","journal-title":"Life Sci"},{"key":"ref=53","first-page":"171","volume":"68","author":"Leung F.W.","year":"2014","unstructured":"Leung F.W.; Capsaicin as an anti-obesity drug. Prog Drug Res 2014,68,171-179","journal-title":"Prog Drug Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2018.05.002","volume":"71","author":"Baggelaar M.P.","year":"2018","unstructured":"Baggelaar M.P.; Maccarrone M.; van der Stelt M.; 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain. Prog Lipid Res 2018,71,1-17","journal-title":"Prog Lipid Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bph.12030","volume":"169","author":"Meijerink J.","year":"2013","unstructured":"Meijerink J.; Balvers M.; Witkamp R.; N-Acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids - from fishy endocannabinoids to potential leads. Br J Pharmacol 2013,169(4),772-783","journal-title":"Br J Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2008.08.001","volume":"120","author":"Woodward D.F.","year":"2008","unstructured":"Woodward D.F.; Carling R.W.C.; Cornell C.L.; The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 2008,120(1),71-80","journal-title":"Pharmacol Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.pbb.2005.01.027","volume":"81","author":"Bisogno T.","year":"2005","unstructured":"Bisogno T.; Ligresti A.; Di Marzo V.; The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005,81(2),224-238","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","volume":"353","author":"Ben-Shabat S.","year":"1998","unstructured":"Ben-Shabat S.; Fride E.; Sheskin T.; An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998,353(1),23-31","journal-title":"Eur J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"14332","DOI":"10.1021\/bi0480335","volume":"43","author":"Saghatelian A.","year":"2004","unstructured":"Saghatelian A.; Trauger S.A.; Want E.J.; Hawkins E.G.; Siuzdak G.; Cravatt B.F.; Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 2004,43(45),14332-14339","journal-title":"Biochemistry"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"11267","DOI":"10.1021\/bi061122s","volume":"45","author":"Mulder A.M.","year":"2006","unstructured":"Mulder A.M.; Cravatt B.F.; Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines. Biochemistry 2006,45(38),11267-11277","journal-title":"Biochemistry"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1381612023395655","volume":"8","author":"Bisogno T.","year":"2002","unstructured":"Bisogno T.; De Petrocellis L.; Di Marzo V.; Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002,8(7),533-547","journal-title":"Curr Pharm Des"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","volume":"14","author":"Blankman J.L.","year":"2007","unstructured":"Blankman J.L.; Simon G.M.; Cravatt B.F.; A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007,14(12),1347-1356","journal-title":"Chem Biol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1054\/plef.2001.0359","volume":"66","author":"Kozak K.R.","year":"2002","unstructured":"Kozak K.R.; Marnett L.J.; Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002,66(2-3),211-220","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0090-6980(01)00105-8","volume":"64","author":"Fukushima N.","year":"2001","unstructured":"Fukushima N.; Chun J.; The LPA receptors. Prostaglandins Other Lipid Mediat 2001,64(1-4),21-32","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0003-9861(02)00038-3","volume":"402","author":"Nakane S.","year":"2002","unstructured":"Nakane S.; Oka S.; Arai S.; 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys 2002,402(1),51-58","journal-title":"Arch Biochem Biophys"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/cvr\/cvv147","volume":"107","author":"Gerhardt T.","year":"2015","unstructured":"Gerhardt T.; Ley K.; Monocyte trafficking across the vessel wall. Cardiovasc Res 2015,107(3),321-330","journal-title":"Cardiovasc Res"},{"key":"ref=67","first-page":"1030","volume":"281","author":"Lake K.D.","year":"1997","unstructured":"Lake K.D.; Compton D.R.; Varga K.; Martin B.R.; Kunos G.; Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997,281(3),1030-1037","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.HYP.29.5.1204","volume":"29","author":"Lake K.D.","year":"1979","unstructured":"Lake K.D.; Martin B.R.; Kunos G.; Varga K.; Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertens Dallas Tex 1979,29(5),1204-0","journal-title":"Hypertens Dallas Tex"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0014-2999(97)01237-5","volume":"335","author":"Randall M.D.","year":"1997","unstructured":"Randall M.D.; Kendall D.A.; Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 1997,335(2-3),205-209","journal-title":"Eur J Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lfs.2014.11.005","volume":"138","author":"Duerr G.D.","year":"2015","unstructured":"Duerr G.D.; Heinemann J.C.; Gestrich C.; Impaired border zone formation and adverse remodeling after reperfused myocardial infarction in cannabinoid CB2 receptor deficient mice. Life Sci 2015,138,8-17","journal-title":"Life Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.bjp.0705155","volume":"138","author":"Hiley C.R.","year":"2003","unstructured":"Hiley C.R.; Ford W.R.; Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction? Br J Pharmacol 2003,138(7),1183-1184","journal-title":"Br J Pharmacol"},{"key":"ref=72","unstructured":""},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","volume":"15","author":"Noyes R.","year":"1975","unstructured":"Noyes R.; Brunk S.F.; Baram D.A.; Canter A.; Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975,15(2-3),139-143","journal-title":"J Clin Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.53.5.436","volume":"53","author":"Frankel J.P.","year":"1990","unstructured":"Frankel J.P.; Hughes A.; Lees A.J.; Stern G.M.; Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990,53(5),436","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0885-3924(97)00038-9","volume":"14","author":"Beal J.E.","year":"1997","unstructured":"Beal J.E.; Olson R.; Lefkowitz L.; Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997,14(1),7-14","journal-title":"J Pain Symptom Manage"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/3-540-26573-2_20","author":"Pacher P.","year":"2005","unstructured":"Pacher P.; B\u00e1tkai S.; Kunos G.; Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005(168),599-625","journal-title":"Handb Exp Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"754.e1","DOI":"10.1016\/j.ahj.2005.11.006","volume":"151","author":"Gorelick D.A.","year":"2006","unstructured":"Gorelick D.A.; Heishman S.J.; Preston K.L.; Nelson R.A.; Moolchan E.T.; Huestis M.A.; The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 2006,151(3),754.e1-754.e5","journal-title":"Am Heart J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"58S","DOI":"10.1002\/j.1552-4604.2002.tb06004.x","volume":"42","author":"Jones R.T.","year":"2002","unstructured":"Jones R.T.; Cardiovascular system effects of marijuana. J Clin Pharmacol 2002,42(S1),58S-63S","journal-title":"J Clin Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s001090050287","volume":"76","author":"Wagner J.A.","year":"1998","unstructured":"Wagner J.A.; Varga K.; Kunos G.; Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med (Berl) 1998,76(12),824-836","journal-title":"J Mol Med (Berl)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nature03389","volume":"434","author":"Steffens S.","year":"2005","unstructured":"Steffens S.; Veillard N.R.; Arnaud C.; Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005,434(7034),782-786","journal-title":"Nature"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0165-5728(02)00370-3","volume":"133","author":"Yuan M.","year":"2002","unstructured":"Yuan M.; Kiertscher S.M.; Cheng Q.; Zoumalan R.; Tashkin D.P.; Roth M.D.; Delta 9-Tetrahydrocannabinol regulates Th1\/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002,133(1-2),124-131","journal-title":"J Neuroimmunol"},{"key":"ref=82","first-page":"H2085","volume":"276","author":"Gebremedhin D.","year":"1999","unstructured":"Gebremedhin D.; Lange A.R.; Campbell W.B.; Hillard C.J.; Harder D.R.; Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca channel current. Am J Physiol 1999,276(6),H2085-H2093","journal-title":"Am J Physiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1042\/bj3460835","volume":"346","author":"Liu J.","year":"2000","unstructured":"Liu J.; Gao B.; Mirshahi F.; Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000,346(Pt 3),835-840","journal-title":"Biochem J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tips.2012.03.002","volume":"33","author":"Montecucco F.","year":"2012","unstructured":"Montecucco F.; Di Marzo V.; At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012,33(6),331-340","journal-title":"Trends Pharmacol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.bbrc.2008.10.159","volume":"377","author":"Rajesh M.","year":"2008","unstructured":"Rajesh M.; Mukhopadhyay P.; Hask\u00f3 G.; Pacher P.; Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008,377(4),1248-1252","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1253\/circj.CJ-11-0366","volume":"75","author":"Curcio A.","year":"2011","unstructured":"Curcio A.; Torella D.; Indolfi C.; Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011,75(6),1287-1296","journal-title":"Circ J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/cvr\/cvn344","volume":"81","author":"Jiang L.S.","year":"2009","unstructured":"Jiang L.S.; Pu J.; Han Z.H.; Hu L.H.; He B.; Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009,81(4),805-813","journal-title":"Cardiovasc Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/cvr\/cvp240","volume":"84","author":"Han K.H.","year":"2009","unstructured":"Han K.H.; Lim S.; Ryu J.; CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 2009,84(3),378-386","journal-title":"Cardiovasc Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1476-5381.2010.00712.x","volume":"160","author":"Rajesh M.","year":"2010","unstructured":"Rajesh M.; Mukhopadhyay P.; Hask\u00f3 G.; Liaudet L.; Mackie K.; Pacher P.; Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 2010,160(3),688-700","journal-title":"Br J Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.811992","volume":"119","author":"Sugamura K.","year":"2009","unstructured":"Sugamura K.; Sugiyama S.; Nozaki T.; Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009,119(1),28-36","journal-title":"Circulation"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/ATVBAHA.108.168757","volume":"29","author":"Dol-Gleizes F.","year":"2009","unstructured":"Dol-Gleizes F.; Paumelle R.; Visentin V.; Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009,29(1),12-18","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00395-010-0090-7","volume":"105","author":"Tiyerili V.","year":"2010","unstructured":"Tiyerili V.; Zimmer S.; Jung S.; CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol 2010,105(4),465-477","journal-title":"Basic Res Cardiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.hjc.2016.11.013","volume":"57","author":"Katsimpoulas M.","year":"2016","unstructured":"Katsimpoulas M.; Kadoglou N.E.; Moustardas P.; The role of exercise training and the endocannabinoid system in atherosclerotic plaque burden and composition in Apo-E-deficient mice. Hellenic J Cardiol 2016,57(6),417-425","journal-title":"Hellenic J Cardiol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"Nissen S.E.","year":"2008","unstructured":"Nissen S.E.; Nicholls S.J.; Wolski K.; Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the stradivarius randomized controlled trial. JAMA 2008,299(13),1547-1560","journal-title":"JAMA"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/hrt.2011.223446","volume":"97","author":"O\u2019Leary D.H.","year":"2011","unstructured":"O\u2019Leary D.H.; Reuwer A.Q.; Nissen S.E.; Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011,97(14),1143-1150","journal-title":"Heart"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2017.01.001","volume":"47","author":"Meletta R.","year":"2017","unstructured":"Meletta R.; Slavik R.; Mu L.; Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [C]RS-016 targeting CB2 in atherosclerosis. Nucl Med Biol 2017,47,31-43","journal-title":"Nucl Med Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"H1145","DOI":"10.1152\/ajpheart.01328.2007","volume":"294","author":"Montecucco F.","year":"2008","unstructured":"Montecucco F.; Burger F.; Mach F.; Steffens S.; CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 2008,294(3),H1145-H1155","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1189\/jlb.0307180","volume":"82","author":"Rajesh M.","year":"2007","unstructured":"Rajesh M.; Pan H.; Mukhopadhyay P.; Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia\/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 2007,82(6),1382-1389","journal-title":"J Leukoc Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"H1064","DOI":"10.1152\/ajpheart.00444.2011","volume":"302","author":"Molica F.","year":"2012","unstructured":"Molica F.; Matter C.M.; Burger F.; Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 2012,302(5),H1064-H1074","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/FJC.0b013e3181d2644d","volume":"55","author":"Zhao Y.","year":"2010","unstructured":"Zhao Y.; Yuan Z.; Liu Y.; Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 2010,55(3),292-298","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1874192401105010015","volume":"5","author":"Delsing D.J.M.","year":"2011","unstructured":"Delsing D.J.M.; Leijten F.P.; Arts K.; Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates early atherosclerosis in ldl receptor deficient mice. Open Cardiovasc Med J 2011,5,15-21","journal-title":"Open Cardiovasc Med J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.yjmcc.2011.08.008","volume":"51","author":"Hoyer F.F.","year":"2011","unstructured":"Hoyer F.F.; Steinmetz M.; Zimmer S.; Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 2011,51(6),1007-1014","journal-title":"J Mol Cell Cardiol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/eurheartj\/ehr449","volume":"33","author":"Montecucco F.","year":"2012","unstructured":"Montecucco F.; Di Marzo V.; da Silva R.F.; The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012,33(7),846-856","journal-title":"Eur Heart J"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2013.12.042","volume":"233","author":"Chiurchi\u00f9 V.","year":"2014","unstructured":"Chiurchi\u00f9 V.; Lanuti M.; Catanzaro G.; Fezza F.; Rapino C.; Maccarrone M.; Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 2014,233(1),55-63","journal-title":"Atherosclerosis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/FJC.0000000000000413","volume":"68","author":"Xu X.","year":"2016","unstructured":"Xu X.; Guo H.; Jing Z.; N-Oleoylethanolamine reduces inflammatory cytokines and adhesion molecules in tnf-\u03b1-induced human umbilical vein endothelial cells by activating cb2 and ppar-\u03b1. J Cardiovasc Pharmacol 2016,68(4),280-291","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"53","DOI":"10.12970\/2311-052X.2015.03.02.2","volume":"3","author":"Netherland-Van Dyke C.","year":"2015","unstructured":"Netherland-Van Dyke C.; Rodgers W.; Fulmer M.; Lahr Z.; Thewke D.; Cannabinoid Receptor Type 2 (CB2) dependent and independent effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice. J Cardiol Ther 2015,3(2),53-63","journal-title":"J Cardiol Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lfs.2016.07.013","volume":"161","author":"Jiang L.","year":"2016","unstructured":"Jiang L.; Chen Y.; Huang X.; Selective activation of CB2 receptor improves efferocytosis in cultured macrophages. Life Sci 2016,161,10-18","journal-title":"Life Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.yjmcc.2018.01.002","volume":"115","author":"Bondarenko A.I.","year":"2018","unstructured":"Bondarenko A.I.; Panasiuk O.; Okhai I.; Montecucco F.; Brandt K.J.; Mach F.; Ca-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation. J Mol Cell Cardiol 2018,115,54-63","journal-title":"J Mol Cell Cardiol"},{"key":"ref=109","first-page":"245","volume":"289","author":"Ishioka N.","year":"1999","unstructured":"Ishioka N.; Bukoski R.D.; A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca-induced relaxation. J Pharmacol Exp Ther 1999,289(1),245-250","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=110","first-page":"819","volume":"297","author":"Szabo B.","year":"2001","unstructured":"Szabo B.; Nordheim U.; Niederhoffer N.; Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 2001,297(2),819-826","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.HYP.35.2.679","volume":"35","author":"J\u00e1rai Z.","year":"1979","unstructured":"J\u00e1rai Z.; Wagner J.A.; Goparaju S.K.; Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertens Dallas Tex 1979,35(2),679-684","journal-title":"Hypertens Dallas Tex"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2008.12.040","volume":"205","author":"Montecucco F.","year":"2009","unstructured":"Montecucco F.; Matias I.; Lenglet S.; Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009,205(2),433-441","journal-title":"Atherosclerosis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.118.311185","volume":"38","author":"Rinne P.","year":"2018","unstructured":"Rinne P.; Guillamat-Prats R.; Rami M.; Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation. Arterioscler Thromb Vasc Biol 2018,38(11),2562-2575","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2015.10.109","volume":"244","author":"Vujic N.","year":"2016","unstructured":"Vujic N.; Schlager S.; Eichmann T.O.; Monoglyceride lipase deficiency modulates endocannabinoid signaling and improves plaque stability in ApoE-knockout mice. Atherosclerosis 2016,244,9-21","journal-title":"Atherosclerosis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"33122","DOI":"10.18632\/oncotarget.16529","volume":"8","author":"Vujic N.","year":"2017","unstructured":"Vujic N.; Korbelius M.; Leopold C.; Monoglyceride lipase deficiency affects hepatic cholesterol metabolism and lipid-dependent gut transit in ApoE-\/- mice. Oncotarget 2017,8(20),33122-33136","journal-title":"Oncotarget"},{"key":"ref=116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197751","volume":"13","author":"Jehle J.","year":"2018","unstructured":"Jehle J.; Sch\u00f6ne B.; Bagheri S.; Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-\/- mice. PLoS One 2018,13(5)","journal-title":"PLoS One"},{"key":"ref=117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146267","volume":"11","author":"Jehle J.","year":"2016","unstructured":"Jehle J.; Hoyer F.F.; Sch\u00f6ne B.; Myeloid-specific deletion of diacylglycerol lipase \u03b1 inhibits atherogenesis in apoe-deficient mice. PLoS One 2016,11(1)","journal-title":"PLoS One"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"H909","DOI":"10.1152\/ajpheart.00373.2007","volume":"293","author":"B\u00e1tkai S.","year":"2007","unstructured":"B\u00e1tkai S.; Rajesh M.; Mukhopadhyay P.; Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2007,293(2),H909-H918","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/ATVBAHA.112.300275","volume":"33","author":"Lenglet S.","year":"2013","unstructured":"Lenglet S.; Thomas A.; Soehnlein O.; Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Arterioscler Thromb Vasc Biol 2013,33(2),215-223","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.yjmcc.2013.11.013","volume":"66","author":"Hoyer F.F.","year":"2014","unstructured":"Hoyer F.F.; Khoury M.; Slomka H.; Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. J Mol Cell Cardiol 2014,66,126-132","journal-title":"J Mol Cell Cardiol"},{"key":"ref=121","volume":"9","author":"Fan A.","year":"2014","unstructured":"Fan A.; Wu X.; Wu H.; Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL. PLoS One 2014,9(1)","journal-title":"PLoS One"},{"key":"ref=122","first-page":"6301","volume":"8","author":"Ma L.","year":"2015","unstructured":"Ma L.; Guo X.; Chen W.; Inhibitory effects of oleoylethanolamide (OEA) on HO-induced human umbilical vein endothelial cell (HUVEC) injury and apolipoprotein E knockout (ApoE-\/-) atherosclerotic mice. Int J Clin Exp Pathol 2015,8(6),6301-6311","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.pharep.2018.06.006","volume":"70","author":"Zhao Y.","year":"2018","unstructured":"Zhao Y.; Yan L.; Peng L.; Oleoylethanolamide alleviates macrophage formation via AMPK\/PPAR\u03b1\/STAT3 pathway. Pharmacol Rep 2018,70(6),1185-1194","journal-title":"Pharmacol Rep"},{"key":"ref=124","volume":"10","author":"Lanuti M.","year":"2015","unstructured":"Lanuti M.; Talamonti E.; Maccarrone M.; Chiurchi\u00f9 V.; Activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages. PLoS One 2015,10(5)","journal-title":"PLoS One"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1160\/TH16-02-0139","volume":"116","author":"Montecucco F.","year":"2016","unstructured":"Montecucco F.; Bondarenko A.I.; Lenglet S.; Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. Thromb Haemost 2016,116(5),987-7","journal-title":"Thromb Haemost"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1194\/jlr.M044669","volume":"55","author":"Hu Y-W.","year":"2014","unstructured":"Hu Y-W.; Yang J-Y.; Ma X.; A lincRNA-DYNLRB2-2\/GPR119\/GLP-1R\/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res 2014,55(4),681-697","journal-title":"J Lipid Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cvr\/cvr245","volume":"92","author":"Ma L.","year":"2011","unstructured":"Ma L.; Zhong J.; Zhao Z.; Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc Res 2011,92(3),504-513","journal-title":"Cardiovasc Res"},{"key":"ref=128","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.146","volume":"5","author":"Li B-H.","year":"2014","unstructured":"Li B-H.; Yin Y-W.; Liu Y.; TRPV1 activation impedes foam cell formation by inducing autophagy in oxLDL-treated vascular smooth muscle cells. Cell Death Dis 2014,5","journal-title":"Cell Death Dis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2017.03.016","volume":"260","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Cui L.; Xu H.; TRPV1 agonism inhibits endothelial cell inflammation via activation of eNOS\/NO pathway. Atherosclerosis 2017,260,13-19","journal-title":"Atherosclerosis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41467-017-02657-z","volume":"9","author":"Gao W.","year":"2018","unstructured":"Gao W.; Sun Y.; Cai M.; Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis. Nat Commun 2018,9(1),231","journal-title":"Nat Commun"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1172\/JCI18730","volume":"114","author":"Li A.C.","year":"2004","unstructured":"Li A.C.; Binder C.J.; Gutierrez A.; Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta\/delta, and gamma. J Clin Invest 2004,114(11),1564-1576","journal-title":"J Clin Invest"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3892\/mmr.2014.2020","volume":"9","author":"Cao H.","year":"2014","unstructured":"Cao H.; Wen G.; Li H.; Role of peroxisome proliferator-activated receptor \u03b1 in atherosclerosis. Mol Med Rep 2014,9(5),1755-1760","journal-title":"Mol Med Rep"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.106.684704","volume":"116","author":"Babaev V.R.","year":"2007","unstructured":"Babaev V.R.; Ishiguro H.; Ding L.; Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007,116(12),1404-1412","journal-title":"Circulation"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1073\/pnas.0510676103","volume":"103","author":"Milman G.","year":"2006","unstructured":"Milman G.; Maor Y.; Abu-Lafi S.; N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 2006,103(7),2428-2433","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/j.1476-5381.2010.00841.x","volume":"160","author":"Zhang X.","year":"2010","unstructured":"Zhang X.; Maor Y.; Wang J.F.; Kunos G.; Groopman J.E.; Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 2010,160(7),1583-1594","journal-title":"Br J Pharmacol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/sj.bjp.0705643","volume":"141","author":"O\u2019Sullivan S.E.","year":"2004","unstructured":"O\u2019Sullivan S.E.; Kendall D.A.; Randall M.D.; Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 2004,141(5),803-812","journal-title":"Br J Pharmacol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1211\/0022357023682","volume":"56","author":"Ho W-S.V.","year":"2004","unstructured":"Ho W-S.V.; Hiley C.R.; Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 2004,56(7),869-875","journal-title":"J Pharm Pharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1476-5381.2010.00770.x","volume":"160","author":"Wheal A.J.","year":"2010","unstructured":"Wheal A.J.; Alexander S.P.H.; Randall M.D.; Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity. Br J Pharmacol 2010,160(3),701-711","journal-title":"Br J Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejphar.2012.03.027","volume":"684","author":"Hopps J.J.","year":"2012","unstructured":"Hopps J.J.; Dunn W.R.; Randall M.D.; Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension. Eur J Pharmacol 2012,684(1-3),102-107","journal-title":"Eur J Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature23292","volume":"548","author":"Foster K.R.","year":"2017","unstructured":"Foster K.R.; Schluter J.; Coyte K.Z.; Rakoff-Nahoum S.; The evolution of the host microbiome as an ecosystem on a leash. Nature 2017,548(7665),43-51","journal-title":"Nature"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bpg.2014.07.005","volume":"28","author":"Moran C.P.","year":"2014","unstructured":"Moran C.P.; Shanahan F.; Gut microbiota and obesity: role in aetiology and potential therapeutic target. Best Pract Res Clin Gastroenterol 2014,28(4),585-597","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"David L.A.","year":"2014","unstructured":"David L.A.; Maurice C.F.; Carmody R.N.; Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014,505(7484),559-563","journal-title":"Nature"},{"key":"ref=143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084689","volume":"9","author":"Finucane M.M.","year":"2014","unstructured":"Finucane M.M.; Sharpton T.J.; Laurent T.J.; Pollard K.S.; A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PLoS One 2014,9(1)","journal-title":"PLoS One"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"Turnbaugh P.J.","year":"2009","unstructured":"Turnbaugh P.J.; Hamady M.; Yatsunenko T.; A core gut microbiome in obese and lean twins. Nature 2009,457(7228),480-484","journal-title":"Nature"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2018.02.036","volume":"271","author":"Kasselman L.J.","year":"2018","unstructured":"Kasselman L.J.; Vernice N.A.; DeLeon J.; Reiss A.B.; The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis 2018,271,203-213","journal-title":"Atherosclerosis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/eji.201646879","volume":"48","author":"Ascher S.","year":"2018","unstructured":"Ascher S.; Reinhardt C.; The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol 2018,48(4),564-575","journal-title":"Eur J Immunol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3389\/fphar.2018.01082","volume":"9","author":"Ma J.","year":"2018","unstructured":"Ma J.; Li H.; The Role of Gut Microbiota in Atherosclerosis and Hypertension. Front Pharmacol 2018,9,1082","journal-title":"Front Pharmacol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/obr.12750","volume":"19","author":"van den Munckhof I.C.L.","year":"2018","unstructured":"van den Munckhof I.C.L.; Kurilshikov A.; Ter Horst R.; Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obes Rev 2018,19(12),1719-1734","journal-title":"Obes Rev"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"Turnbaugh P.J.","year":"2006","unstructured":"Turnbaugh P.J.; Ley R.E.; Mahowald M.A.; Magrini V.; Mardis E.R.; Gordon J.I.; An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006,444(7122),1027-1031","journal-title":"Nature"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1073\/pnas.0605374104","volume":"104","author":"B\u00e4ckhed F.","year":"2007","unstructured":"B\u00e4ckhed F.; Manchester J.K.; Semenkovich C.F.; Gordon J.I.; Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007,104(3),979-984","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=151","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241214","volume":"341","author":"Ridaura V.K.","year":"2013","unstructured":"Ridaura V.K.; Faith J.J.; Rey F.E.; Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013,341(6150)","journal-title":"Science"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","volume":"143","author":"Vrieze A.","year":"2012","unstructured":"Vrieze A.; Van Nood E.; Holleman F.; Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012,143(4),913-6.e7","journal-title":"Gastroenterology"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.1011383107","volume":"108","author":"Koren O.","year":"2011","unstructured":"Koren O.; Spor A.; Felin J.; Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011,108(Suppl. 1),4592-4598","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/CIRCRESAHA.116.309219","volume":"119","author":"Kelly T.N.","year":"2016","unstructured":"Kelly T.N.; Bazzano L.A.; Ajami N.J.; Gut microbiome associates with lifetime cardiovascular disease risk profile among bogalusa heart study participants. Circ Res 2016,119(8),956-964","journal-title":"Circ Res"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"908","DOI":"10.5551\/jat.32672","volume":"23","author":"Emoto T.","year":"2016","unstructured":"Emoto T.; Yamashita T.; Sasaki N.; Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb 2016,23(8),908-921","journal-title":"J Atheroscler Thromb"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ncomms2266","volume":"3","author":"Karlsson F.H.","year":"2012","unstructured":"Karlsson F.H.; F\u00e5k F.; Nookaew I.; Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012,3,1245","journal-title":"Nat Commun"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41467-017-00900-1","volume":"8","author":"Jie Z.","year":"2017","unstructured":"Jie Z.; Xia H.; Zhong S-L.; The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017,8(1),845","journal-title":"Nat Commun"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13668-018-0248-8","volume":"7","author":"Chambers E.S.","year":"2018","unstructured":"Chambers E.S.; Preston T.; Frost G.; Morrison D.J.; Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep 2018,7(4),198-206","journal-title":"Curr Nutr Rep"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI41651","volume":"121","author":"Lukasova M.","year":"2011","unstructured":"Lukasova M.; Malaval C.; Gille A.; Kero J.; Offermanns S.; Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011,121(3),1163-1173","journal-title":"J Clin Invest"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1194\/jlr.R088989","volume":"60","author":"Kriaa A.","year":"2019","unstructured":"Kriaa A.; Bourgin M.; Potiron A.; Microbial impact on cholesterol and bile acid metabolism: current status and future prospects. J Lipid Res 2019,60(2),323-332","journal-title":"J Lipid Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13098-017-0299-9","volume":"9","author":"Ryan P.M.","year":"2017","unstructured":"Ryan P.M.; Stanton C.; Caplice N.M.; Bile acids at the cross-roads of gut microbiome\u2013host cardiometabolic interactions. Diabetol Metab Syndr 2017,9,102","journal-title":"Diabetol Metab Syndr"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"s43","DOI":"10.5604\/01.3001.0010.5496","volume":"16","author":"V\u00edtek L.","year":"2017","unstructured":"V\u00edtek L.; Bile acids in the treatment of cardiometabolic diseases. Ann Hepatol 2017,16(1),s43-s52","journal-title":"Ann Hepatol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/ejcn.2012.126","volume":"66","author":"Jones M.L.","year":"2012","unstructured":"Jones M.L.; Martoni C.J.; Prakash S.; Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 2012,66(11),1234-1241","journal-title":"Eur J Clin Nutr"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","volume":"26","author":"Zhang Y.","year":"2006","unstructured":"Zhang Y.; Wang X.; Vales C.; FXR deficiency causes reduced atherosclerosis in Ldlr-\/- mice. Arterioscler Thromb Vasc Biol 2006,26(10),2316-2321","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.bbalip.2006.09.018","volume":"1761","author":"Guo G.L.","year":"2006","unstructured":"Guo G.L.; Santamarina-Fojo S.; Akiyama T.E.; Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 2006,1761(12),1401-1409","journal-title":"Biochim Biophys Acta"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","volume":"46","author":"Hanniman E.A.","year":"2005","unstructured":"Hanniman E.A.; Lambert G.; McCarthy T.C.; Sinal C.J.; Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 2005,46(12),2595-2604","journal-title":"J Lipid Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1194\/jlr.M017376","volume":"52","author":"Sui Y.","year":"2011","unstructured":"Sui Y.; Xu J.; Rios-Pilier J.; Zhou C.; Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J Lipid Res 2011,52(9),1652-1659","journal-title":"J Lipid Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/ATVBAHA.110.213496","volume":"31","author":"Skoura A.","year":"2011","unstructured":"Skoura A.; Michaud J.; Im D.S.; Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011,31(1),81-85","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","volume":"14","author":"Pols T.W.H.","year":"2011","unstructured":"Pols T.W.H.; Nomura M.; Harach T.; TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011,14(6),747-757","journal-title":"Cell Metab"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.nut.2015.05.006","volume":"31","author":"Ufnal M.","year":"2015","unstructured":"Ufnal M.; Zadlo A.; Ostaszewski R.; TMAO: A small molecule of great expectations. Nutrition 2015,31(11-12),1317-1323","journal-title":"Nutrition"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cmet.2012.12.011","volume":"17","author":"Bennett B.J.","year":"2013","unstructured":"Bennett B.J.; de Aguiar Vallim T.Q.; Wang Z.; Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013,17(1),49-60","journal-title":"Cell Metab"},{"key":"ref=172","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002767","volume":"5","author":"Seldin M.M.","year":"2016","unstructured":"Seldin M.M.; Meng Y.; Qi H.; Trimethylamine N-Oxide Promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-\u03baB. J Am Heart Assoc 2016,5(2)","journal-title":"J Am Heart Assoc"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/jpet.116.233296","volume":"358","author":"Spector R.","year":"2016","unstructured":"Spector R.; New insight into the dietry cause of atherosclerosis: implications for pharmacology. J Pharmacol Exp Ther 2016,358(1),103-108","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"Schiattarella G.G.","year":"2017","unstructured":"Schiattarella G.G.; Sannino A.; Toscano E.; Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis. Eur Heart J 2017,38(39),2948-2956","journal-title":"Eur Heart J"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1074\/jbc.M114.618249","volume":"290","author":"Gregory J.C.","year":"2015","unstructured":"Gregory J.C.; Buffa J.A.; Org E.; Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015,290(9),5647-5660","journal-title":"J Biol Chem"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.cell.2015.11.055","volume":"163","author":"Wang Z.","year":"2015","unstructured":"Wang Z.; Roberts A.B.; Buffa J.A.; Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015,163(7),1585-1595","journal-title":"Cell"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Wang Z.","year":"2011","unstructured":"Wang Z.; Klipfell E.; Bennett B.J.; Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011,472(7341),57-63","journal-title":"Nature"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.10.108","volume":"244","author":"Collins H.L.","year":"2016","unstructured":"Collins H.L.; Drazul-Schrader D.; Sulpizio A.C.; L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-\/-) transgenic mice expressing CETP. Atherosclerosis 2016,244,29-37","journal-title":"Atherosclerosis"},{"key":"ref=179","doi-asserted-by":"publisher","DOI":"10.1080\/16512235.2017.1327309","volume":"28","author":"Landfald B.","year":"2018","unstructured":"Landfald B.; Valeur J.; Berstad A.; Raa J.; Microbial trimethylamine-N-oxide as a disease marker: something fishy? Microb Ecol Health Dis 2018,28(1)","journal-title":"Microb Ecol Health Dis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/nutrit\/nuv004","volume":"73","author":"Graham C.","year":"2015","unstructured":"Graham C.; Mullen A.; Whelan K.; Obesity and the gastrointestinal microbiota: a review of associations and mechanisms. Nutr Rev 2015,73(6),376-385","journal-title":"Nutr Rev"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2741\/S405","volume":"1","author":"Glaros T.G.","year":"2013","unstructured":"Glaros T.G.; Chang S.; Gilliam E.A.; Maitra U.; Deng H.; Li L.;  Front Biosci Sch Ed 2013,1(5),754-65","journal-title":"Front Biosci Sch Ed"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1530\/JME-13-0079","volume":"51","author":"Neves A.L.","year":"2013","unstructured":"Neves A.L.; Coelho J.; Couto L.; Leite-Moreira A.; Roncon-Albuquerque R.; Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol 2013,51(2),R51-R64","journal-title":"J Mol Endocrinol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","volume":"57","author":"Bujak M.","year":"2009","unstructured":"Bujak M.; Frangogiannis N.G.; The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 2009,57(3),165-176","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2013.07.004","volume":"230","author":"Serrano M.","year":"2013","unstructured":"Serrano M.; Moreno-Navarrete J.M.; Puig J.; Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. Atherosclerosis 2013,230(2),223-227","journal-title":"Atherosclerosis"},{"key":"ref=185","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005784","volume":"6","author":"Pastori D.","year":"2017","unstructured":"Pastori D.; Carnevale R.; Nocella C.; Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular events in atrial fibrillation: effect of adherence to mediterranean diet. J Am Heart Assoc 2017,6(6)","journal-title":"J Am Heart Assoc"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1183\/13993003.00972-2015","volume":"48","author":"Jaw J.E.","year":"2016","unstructured":"Jaw J.E.; Tsuruta M.; Oh Y.; Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation. Eur Respir J 2016,48(1),205-215","journal-title":"Eur Respir J"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/hc3401.093153","volume":"104","author":"Lehr H.A.","year":"2001","unstructured":"Lehr H.A.; Sagban T.A.; Ihling C.; Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001,104(8),914-920","journal-title":"Circulation"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.1073\/pnas.0403249101","volume":"101","author":"Michelsen K.S.","year":"2004","unstructured":"Michelsen K.S.; Wong M.H.; Shah P.K.; Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004,101(29),10679-10684","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1161\/ATVBAHA.112.249847","volume":"32","author":"Ding Y.","year":"2012","unstructured":"Ding Y.; Subramanian S.; Montes V.N.; Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2012,32(7),1596-1604","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/CIRCULATIONAHA.115.019645","volume":"133","author":"Li J.","year":"2016","unstructured":"Li J.; Lin S.; Vanhoutte P.M.; Woo C.W.; Xu A.; Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-\/- Mice. Circulation 2016,133(24),2434-2446","journal-title":"Circulation"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/msb.2010.46","author":"Muccioli G.G.","year":"2010","unstructured":"Muccioli G.G.; Naslain D.; B\u00e4ckhed F.; The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010,392","journal-title":"Mol Syst Biol"},{"key":"ref=192","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00149","author":"Geurts L.","unstructured":"Geurts L.; Lazarevic V.; Derrien M.; Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol","journal-title":"Front Microbiol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1432-1327.1999.00631.x","volume":"264","author":"Di Marzo V.","year":"1999","unstructured":"Di Marzo V.; Bisogno T.; De Petrocellis L.; Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999,264(1),258-267","journal-title":"Eur J Biochem"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.physbeh.2018.11.035","volume":"199","author":"Grunewald Z.I.","year":"2019","unstructured":"Grunewald Z.I.; Lee S.; Kirkland R.; Ross M.; de La Serre C.B.; Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. Physiol Behav 2019,199,282-291","journal-title":"Physiol Behav"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/clp.13.80","volume":"9","author":"Rohla M.","year":"2014","unstructured":"Rohla M.; Weiss T.W.; Adipose tissue, inflammation and atherosclerosis. Clin Lipidol 2014,9(1),71-81","journal-title":"Clin Lipidol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-18-0082","volume":"238","author":"Nagareddy P.R.","year":"2018","unstructured":"Nagareddy P.R.; Noothi S.K.; Flynn M.C.; Murphy A.J.; It\u2019s reticulated: the liver at the heart of atherosclerosis. J Endocrinol 2018,238(1),R1-R11","journal-title":"J Endocrinol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm1521","volume":"13","author":"Rousseaux C.","year":"2007","unstructured":"Rousseaux C.; Thuru X.; Gelot A.; Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007,13(1),35-37","journal-title":"Nat Med"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","volume":"110","author":"Everard A.","year":"2013","unstructured":"Everard A.; Belzer C.; Geurts L.; Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013,110(22),9066-9071","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1111\/nmo.12154","volume":"25","author":"Aguilera M.","year":"2013","unstructured":"Aguilera M.; Vergara P.; Mart\u00ednez V.; Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice. Neurogastroenterol Motil 2013,25(8),e515-e529","journal-title":"Neurogastroenterol Motil"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbi.2017.09.001","volume":"67","author":"Guida F.","year":"2018","unstructured":"Guida F.; Turco F.; Iannotta M.; Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun 2018,67,230-245","journal-title":"Brain Behav Immun"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41598-017-01322-1","volume":"7","author":"Gioacchini G.","year":"2017","unstructured":"Gioacchini G.; Rossi G.; Carnevali O.; Host-probiotic interaction: new insight into the role of the endocannabinoid system by in vivo and ex vivo approaches. Sci Rep 2017,7(1),1261","journal-title":"Sci Rep"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1038\/ncomms7495","volume":"6","author":"Geurts L.","year":"2015","unstructured":"Geurts L.; Everard A.; Van Hul M.; Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat Commun 2015,6,6495","journal-title":"Nat Commun"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1038\/s41598-017-15154-6","volume":"7","author":"Mehrpouya-Bahrami P.","year":"2017","unstructured":"Mehrpouya-Bahrami P.; Chitrala K.N.; Ganewatta M.S.; Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep 2017,7(1),15645","journal-title":"Sci Rep"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/adb.12116","volume":"20","author":"Ceccarini J.","year":"2015","unstructured":"Ceccarini J.; Kuepper R.; Kemels D.; van Os J.; Henquet C.; Van Laere K.; [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol 2015,20(2),357-367","journal-title":"Addict Biol"},{"key":"ref=205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144270","volume":"10","author":"Cluny N.L.","year":"2015","unstructured":"Cluny N.L.; Keenan C.M.; Reimer R.A.; Le Foll B.; Sharkey K.A.; Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with \u0394-Tetrahydrocannabinol. PLoS One 2015,10(12)","journal-title":"PLoS One"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"E4825","DOI":"10.1073\/pnas.1508737112","volume":"112","author":"Cohen L.J.","year":"2015","unstructured":"Cohen L.J.; Kang H-S.; Chu J.; Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A\/132 agonist. Proc Natl Acad Sci USA 2015,112(35),E4825-E4834","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature23874","volume":"549","author":"Cohen L.J.","year":"2017","unstructured":"Cohen L.J.; Esterhazy D.; Kim S-H.; Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 2017,549(7670),48-53","journal-title":"Nature"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1161\/CIRCRESAHA.108.181131","volume":"104","author":"Bolick D.T.","year":"2009","unstructured":"Bolick D.T.; Skaflen M.D.; Johnson L.E.; G2A deficiency in mice promotes macrophage activation and atherosclerosis. Circ Res 2009,104(3),318-327","journal-title":"Circ Res"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1172\/JCI72517","volume":"124","author":"Chen Z.","year":"2014","unstructured":"Chen Z.; Guo L.; Zhang Y.; Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest 2014,124(8),3391-3406","journal-title":"J Clin Invest"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41598-018-37373-1","volume":"9","author":"May-Zhang L.S.","year":"2019","unstructured":"May-Zhang L.S.; Chen Z.; Dosoky N.S.; Administration of N-AcylPhosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor\u2212\/\u2212 Mice Improves Indices of Cardiometabolic Disease. Sci Rep 2019,9,420","journal-title":"Sci Rep"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2826.2008.01689.x","volume":"20","author":"Dalle Carbonare M.","year":"2008","unstructured":"Dalle Carbonare M.; Del Giudice E.; Stecca A.; A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story..... J Neuroendocrinol 2008,20(Suppl. 1),26-34","journal-title":"J Neuroendocrinol"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T05:58:01Z","timestamp":1575611881000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174465\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":211,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,10,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190826162735","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}